Interpretation of pTau217 Level of 0.374
A plasma pTau217 level of 0.374 pg/mL falls into an intermediate probability zone for Alzheimer's disease pathology and requires confirmatory testing with either amyloid PET or CSF biomarkers before making definitive clinical decisions.
Context-Dependent Interpretation
The interpretation of this specific value depends critically on which assay platform was used and the clinical context, but based on the most recent evidence using automated platforms:
Platform-Specific Thresholds
Using the Lumipulse G platform (the most validated automated system), a value of 0.374 pg/mL falls between established dual-threshold cutoffs 1, 2:
- Rule-out threshold: 0.146 pg/mL (≥97.5% sensitivity)
- Rule-in threshold: 0.486 pg/mL (≥97.5% specificity)
Your value of 0.374 sits in the "gray zone" between these thresholds, meaning:
- It's above the rule-out threshold → cannot confidently exclude AD pathology
- It's below the rule-in threshold → cannot confidently confirm AD pathology
Probability Assessment
At this intermediate level, the likelihood of underlying amyloid pathology is uncertain and requires additional testing 1, 2. Recent multicenter validation showed that approximately 42.7% of patients fall into this intermediate zone when using strict dual thresholds 1.
Recommended Clinical Approach
Do not make treatment decisions based on this result alone. The 2025 Alzheimer's Association guidelines emphasize that blood biomarkers should be used within a structured diagnostic workflow 3.
Next Steps:
Obtain confirmatory testing with either:
- Amyloid PET imaging (preferred if available)
- CSF biomarkers (Aβ42/Aβ40 ratio)
Consider the pTau217/Aβ1-42 ratio if plasma Aβ1-42 was measured simultaneously, as this combination reduces indeterminate results from 38.6% to 26.5% while maintaining >94% positive and negative predictive values 4
Integrate with clinical context:
- Cognitive status (cognitively unimpaired vs. MCI vs. dementia)
- APOE genotype if available
- Other clinical features and neuroimaging
Important Caveats
Assay-Specific Considerations
Different platforms yield different absolute concentrations despite excellent correlation 2. Platform-specific thresholds are not interchangeable - a value of 0.374 on Lumipulse may not mean the same as 0.374 on Cobas e801 or mass spectrometry platforms 2.
Clinical Context Matters
- In cognitively unimpaired individuals: pTau217 shows 82% sensitivity and 86% specificity for amyloid pathology, but positive predictive value is only 79% as a stand-alone test 5, 6
- In MCI/dementia: Diagnostic accuracy improves significantly, with pTau217 performing comparably to CSF biomarkers and tau-PET 7
Comorbidity Effects
Be aware that cardiovascular disease and diabetes may reduce specificity of standard pTau217 measurements 8. If significant comorbidities are present, confirmatory testing becomes even more critical.
What This Value Does NOT Tell You
- It does not diagnose or exclude AD definitively at this intermediate level
- It does not predict rate of cognitive decline with precision at individual level
- It should not be used alone to initiate or withhold disease-modifying therapies
The 2-step approach (plasma screening followed by PET/CSF confirmation for intermediate values) achieves 91% positive predictive value and 95.3% overall accuracy 1, 5, making it the most appropriate strategy for your patient with this borderline result.